

Ref no: 121100920
From: Commercial
Date: 10/09/20
Subject: Biologic and biosimilar product prescribing in Rheumatology

REQUEST

I have a Freedom of Information request regarding biologic and biosimilar product prescribing in **rheumatology**.

Q1. How many patients have been treated with biologics or biosimilar products in the last 12 months for the following conditions:

- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Non-Radiographic Axial Spondyloarthritis

Q2. Could you please provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 12 months with the following drugs.

- Abatacept [Orencia]
- Adalimumab [Amgevita]
- Adalimumab [Humira]
- Adalimumab [Hyrimoz]
- Adalimumab [Imraldi]
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Certolizumab [Cimzia]

- Etanercept [Benepali]
- Etanercept [Enbrel]
- Etanercept [Erelzi]
- Golimumab [Simponi]
- Infliximab [Flixabi]
- Infliximab [Inflectra]
- Infliximab [Remicade]
- Infliximab [Remsima]
- Ixekizumab [Taltz]
- Rituximab [MabThera]
- Rituximab [Rixathon]
- Rituximab [Truxima]
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

RESPONSE

Q1. The Trust does not hold the information.

Q2

The table below shows the number of patients treated with each named drug within Rheumatology between 1st September 2019 and 1st September 2020:

ABATACEPT	9
ABATACEPT [:S/C]	27
ADALIMUMAB "AMGEVITA"	128
ADALIMUMAB "HUMIRA"	101
APREMILAST	<5
APREMILAST INITIATION PACK	<5
BARICITINIB	43
CERTOLIZUMAB PEGOL	20
ETANERCEPT [:BENEPALI 25mg]	<5
ETANERCEPT [:BENEPALI 50mg]	112
ETANERCEPT [:ENBREL 25mg]	38
ETANERCEPT [:ENBREL 50mg]	22
GOLIMUMAB	39
INFLIXIMAB 'REMICADE'	<5
INFLIXIMAB 'REMSIMA'	<5
INFLIXIMAB 'REMSIMA' [:FKLD1227]	<5
INFLIXIMAB 'REMSIMA' [FKLD1135]	<5
INFLIXIMAB 'REMSIMA' [FKLD1136]	<5
INFLIXIMAB 'REMSIMA' [FKLD1138]	<5
INFLIXIMAB 'REMSIMA' [FKLD1140]	<5
RITUXIMAB (MABTHERA)	<5
RITUXIMAB (TRUXIMA)	49
SECUKINUMAB	22
TOCILIZUMAB	36
TOFACITINIB	9
USTEKINUMAB	6

NB

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed "lawfully, fairly and in a transparent manner". It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.